Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel, Arnaud
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. [electronic resource] - The Lancet. Oncology 02 2019 - 239-253 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1474-5488
10.1016/S1470-2045(18)30765-4 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--administration & dosage
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Ipilimumab--administration & dosage
Lung Neoplasms--drug therapy
Male
Mesothelioma--drug therapy
Mesothelioma, Malignant
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Nivolumab--administration & dosage
Pleural Neoplasms--drug therapy
Prospective Studies
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. [electronic resource] - The Lancet. Oncology 02 2019 - 239-253 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1474-5488
10.1016/S1470-2045(18)30765-4 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological--administration & dosage
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Ipilimumab--administration & dosage
Lung Neoplasms--drug therapy
Male
Mesothelioma--drug therapy
Mesothelioma, Malignant
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Nivolumab--administration & dosage
Pleural Neoplasms--drug therapy
Prospective Studies